[Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation].

Authors :: Bibault JE
Oudoux A
Durand-Labrunie J
Mirabel X
Lartigau É
Kolesnikov-Gauthier H
Source :: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2015 Dec; Vol. 19 (8), pp. 790-4; quiz 795-9. Date of Electronic Publication: 2015 Oct 21.
Publication Year :: 2015
Abstract: Stereotactic body radiation therapy is the standard treatment for inoperable patients with early-stage lung cancer. Local control rates range from 80 to 90 % 2 years after treatment. The role of positron emission tomography in patient selection is well known, but its use for target definition or therapeutic response evaluation is less clear. We reviewed the literature in order to assess the current state of knowledge in this area.<br /> (Copyright © 2015 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.)

Subjects :: Fluorodeoxyglucose F18
Humans
Patient Care Planning
Radiopharmaceuticals
Lung Neoplasms diagnostic imaging
Lung Neoplasms surgery
Positron-Emission Tomography
Radiosurgery

Language :: French
ISSN :: 1769-6658
Volume :: 19
Issue :: 8
Database :: MEDLINE
Journal :: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Publication Type :: Academic Journal
Accession number :: 26476702
Full Text :: https://doi.org/10.1016/j.canrad.2015.05.027

Full Text Access

Tools